YERVOY (ipilimumab)
ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB·METASTATIC MALIGNANT MELANOMA·+8
BMS PRIMARYCARE
Indication
EGFR negative, ALK negative, non-small cell lung cancer
Epidermal growth factor receptor (EGFR)-negative, anaplastic lymphoma kinase (ALK)-negative non-small cell lung cancer denotes a molecular subset of non-small cell lung carcinoma—primarily adenocarcinoma or large cell carcinoma of the respiratory tract—whose neoplastic cells lack sensitizing mutations in the *EGFR* gene and rearrangements involving the *ALK* gene. Read more about EGFR negative, ALK negative, non-small cell lung cancer
13 drugs 10 manufacturers
Drugs that treat it
Common EGFR negative, ALK negative, non-small cell lung cancer therapies.
KEYTRUDA POWDER (pembrolizumab)
MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
OPDIVO (nivolumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT ESOPHAGEAL NEOPLASM·+17
BMS PRIMARYCARE
KEYTRUDA (pembrolizumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
IMFINZI (durvalumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BILIARY TRACT MALIGNANCY·+10
AstraZeneca Pharmaceuticals
IMJUDO (tremelimumab-actl)
ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB·LIVER CELL CARCINOMA·+1
AstraZeneca Pharmaceuticals
PEMRYDI RTU (pemetrexed disodium)
FOLATE ANTAGONISTS·MALIGNANT MESOTHELIOMA OF PLEURA·+2
Amneal Pharmaceuticals
AXTLE (pemetrexed dipotassium)
FOLATE ANTAGONISTS·MALIGNANT MESOTHELIOMA OF PLEURA·+2
AVYXA PHARMA, L
PEMETREXED
FOLATE ANTAGONISTS·MALIGNANT MESOTHELIOMA OF PLEURA·+2
TEVA USA
Filter & compare in the drug finder →Opens the drug finder with EGFR negative, ALK negative, non-small cell lung cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEpidermal growth factor receptor (EGFR)-negative, anaplastic lymphoma kinase (ALK)-negative non-small cell lung cancer denotes a molecular subset of non-small cell lung carcinoma—primarily adenocarcinoma or large cell carcinoma of the respiratory tract—whose neoplastic cells lack sensitizing mutations in the *EGFR* gene and rearrangements involving the *ALK* gene.
Affecting adult patients with primary pulmonary malignancies, this clinical state is pathologically defined by the absence of these two primary oncogenic driver alterations that typically confer sensitivity to targeted receptor tyrosine kinase inhibitors.
Consequently, tumors exhibiting this wild-type biomarker profile lack dependence on EGFR or ALK signaling cascades, distinguishing them biologically from oncogene-addicted lung cancers and determining eligibility for alternative standard systemic regimens, such as immune checkpoint inhibitors and cytotoxic chemotherapy combinations.
- nih.gov
Epidermal growth factor receptor (EGFR)-negative, anaplastic lymphoma kinase (ALK)-negative non-small cell lung cancer denotes a molecular subset of non-small cell lung carcinoma—primarily adenocarcinoma or large cell carcinoma of the respiratory tract—whose neoplastic cells lack sensitizing mutations in the *EGFR* gene and rearrangements involving the *ALK* gene Affecting adult patients with primary pulmonary malignancies, this clinical state is pathologically defined by the absence of these tw...
- lungevity.org
Epidermal growth factor receptor (EGFR)-negative, anaplastic lymphoma kinase (ALK)-negative non-small cell lung cancer denotes a molecular subset of non-small cell lung carcinoma—primarily adenocarcinoma or large cell carcinoma of the respiratory tract—whose neoplastic cells lack sensitizing mutations in the *EGFR* gene and rearrangements involving the *ALK* gene
- go2.org
Affecting adult patients with primary pulmonary malignancies, this clinical state is pathologically defined by the absence of these two primary oncogenic driver alterations that typically confer sensitivity to targeted receptor tyrosine kinase inhibitors
Personalize your experience
Follow EGFR negative, ALK negative, non-small cell lung cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.